Ibex Biosciences Patents – Insights & Stats (Updated 2024)

Ibex Biosciences has a total of 36 patents globally, out of which 1 has been granted. Of these 36 patents, more than 88% patents are active. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Ibex Biosciences.

Ibex Biosciences was founded in the year 2015. The Company works on many different projects to find solutions for big problems in health and the environment. They try out new ideas and processes that haven’t been proven by other researchers yet.

Do read about some of the most popular patents of Ibex Biosciences which have been covered by us in this article and also you can find Ibex Biosciences patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Ibex Biosciences patent portfolio.

How many patents does Ibex Biosciences have?

Ibex Biosciences has a total of 36 patents globally. These patents belong to 5 unique patent families. Out of 36 patents, 32 patents are active.

How Many Patents did Ibex Biosciences File Every Year?

Ibex Biosciences Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantIbex Biosciences Applications FiledIbex Biosciences Patents Granted
202321
202211
20211
20208
201914

How many Ibex Biosciences patents are Alive/Dead?

Ibex Biosciences Patent Portfolio

 How Many Patents did Ibex Biosciences File in Different Countries?

Ibex Biosciences Worldwide Patent Filing

Countries in which Ibex Biosciences Filed Patents

CountryPatents
Israel4
Europe4
Australia4
United States Of America4
Canada4
China4
India3
African Regional Industrial Property Organization1
Mexico1
Brazil1
South Africa1
South Korea1

Where are Research Centres of Ibex Biosciences Patents Located?

R&D Centers of Ibex Biosciences

What Percentage of Ibex Biosciences US Patent Applications were Granted?

Ibex Biosciences (Excluding its subsidiaries) has filed 3 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 0 have been granted leading to a grant rate of 0.0%.

Below are the key stats of Ibex Biosciences patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Ibex Biosciences?

Law FirmTotal ApplicationsSuccess Rate
Cooley Llp30%

List of Ibex Biosciences Patents

Ibex Biosciences PatentsTitle
US20240010723A1Antibodies Targeted To Cd147
US20220228126A1Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis
US20220025025A1Antibodies Directed To Filamin-A And Therapeutic Uses Thereof
US20210113714A1Use Of Pcbp1 To Treat Hyperproliferative Disease
EP4274615A1Antibodies Targeted To Cd147
EP4010471A4Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis
EP3863687A4Antibodies Directed To Filamin-A And Therapeutic Uses Thereof
EP3749763A4Use Of Pcbp1 To Treat Hyperproliferative Disease
CN113164633BAntibodies Against Filamin-A And Their Therapeutic Uses
CN116887861AAntibodies Targeting Cd147
CN114402072AApplication Of Pcbp1 To Generation Of Induced Pluripotent Stem Cells And Inhibition Of Tumorigenesis
CN111757933AUse Of Pcbp1 To Treat Hyperproliferative Disease
IL304093AAntibodies Targeted To Cd147
AU2022205427A1Antibodies Targeted To Cd147
CA3204047A1Antibodies Targeted To Cd147
IL290162AUse Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis
AU2020325311A1Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis
IL281932AAntibodies Directed To Filamin-A And Therapeutic Uses Thereof
AU2019358060A1Antibodies Directed To Filamin-A And Therapeutic Uses Thereof
CA3149640A1Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis
IL276382A0Use Of Pcbp1 To Treat Hyperproliferative Disease
AU2019215464A1Use Of Pcbp1 To Treat Hyperproliferative Disease
CA3115077A1Antibodies Directed To Filamin-A And Therapeutic Uses Thereof
CA3089731A1Use Of Pcbp1 To Treat Hyperproliferative Disease
IN202247011039AUse Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis
IN202147020127AAntibodies Directed To Filamin-A And Therapeutic Uses Thereof
IN202047037165AUse Of Pcbp1 To Treat Hyperproliferative Disease
KR1020230131478AAntibodies Targeting Cd147
BR112023013543A2Antibodies Targeted To Cd147
APP2023015045A0Antibodies Targeted To Cd147
ZA202306655AAntibodies Targeted To Cd147
MX2020008243AUse Of Pcbp1 To Treat Hyperproliferative Disease.
WO2022150759A1Antibodies Targeted To Cd147
WO2021026488A3Use Of Pcbp1 To Generate Induced Pluripotent Stem Cells While Inhibiting Oncogenesis
WO2020076954A1Antibodies Directed To Filamin-A And Therapeutic Uses Thereof
WO2019153008A1Use Of Pcbp1 To Treat Hyperproliferative Disease

What are Ibex Biosciences key innovation segments?

What Technologies are Covered by Ibex Biosciences?

The chart below distributes patents filed by Ibex Biosciences in different countries on the basis of the technology protected in patents. It also represents the markets where Ibex Biosciences thinks it’s important to protect particular technology inventions.

R&D Focus: How has Ibex Biosciences search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Ibex Biosciences?

Related Articles

Arashi Vision Patents – Insights & Stats (Updated 2024)

Arashi Vision has a total of 1257 patents globally, out of which 751 have been granted. Of these 1257 patents, more than 87% patents are active. China is where Arashi Vision has filed the maximum number of patents, followed by United States of America and Europe (EPO). Parallelly, China seems

Read More »

Terecircuits Patents – Insights & Stats (Updated 2024)

Terecircuits has a total of 43 patents globally, out of which 22 have been granted. Of these 43 patents, more than 37% patents are active. United States of America is where Terecircuits has filed the maximum number of patents, followed by Europe (EPO) and Taiwan. Parallelly, United States of America

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.